Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

GlobalData, September 2011, Pages: 44

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

Summary

Synta Pharmaceuticals Corp. (Synta Pharmaceutical) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel pharmaceutical products for the treatment of severe medical conditions such as cancer, autoimmune and chronic inflammatory diseases. The company has unique chemical compound library, an integrated discovery engine, and aslo diverse pipeline of clinical- and preclinical-stage drug candidates. It also have three clinical-stage drug candidates and several drug candidates in the preclinical and discovery stages. The company focused on the research and development activities for the development of new products. The company mainly operates in the US. Synta Pharmaceutical is headquartered in Massachusetts, the US.

Synta Pharmaceuticals Corp. Key Recent Developments

Aug 04, 2011 Synta Reports Total Revenue Of $1.3m For Q2 2011
May 05, 2011 Synta Pharmaceuticals Reports Net Loss Of $11.4m For Q1 2011
Apr 04, 2011 Synta Announces Ganetespib Results At AACR
Mar 11, 2011 Synta Reports Net Loss Of $8.8m For Q4 2010
Mar 10, 2011 Insmed Reports Net Loss Of $5.8m For Q4 2010

This comprehensive SWOT profile of Synta Pharmaceuticals Corp. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
Synta Pharmaceuticals Corp. - Key Facts
Synta Pharmaceuticals Corp. - Key Employees
Synta Pharmaceuticals Corp. - Key Employee Biographies
Synta Pharmaceuticals Corp. - Major Products and Services
Synta Pharmaceuticals Corp. - Pharmaceutical Pipeline Products Data
Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Pipeline Products by Development Phase
Synta Pharmaceuticals Corp. - History
Synta Pharmaceuticals Corp. - Company Statement
Synta Pharmaceuticals Corp. - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Synta Pharmaceuticals Corp. - Business Description
Synta Pharmaceuticals Corp. - Corporate Strategy
Synta Pharmaceuticals Corp. - SWOT Analysis
SWOT Analysis - Overview
Synta Pharmaceuticals Corp. - Strengths
Strength - Strong Intellectual Property Portfolio
Strength - Diverse Pipeline Drug Candidates
Strength - Strong Liquidity Position
Weakness - High Operating Costs affecting Margins
Weakness - Asset Inefficiencies
Opportunity - Strategic Collaborations
Opportunity - Market Potential: Cancer
Opportunity - Emerging Markets
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Threat - Stringent Government Regulations
Synta Pharmaceuticals Corp. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Synta Pharmaceuticals Corp., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 04, 2011: Synta Reports Total Revenue Of $1.3m For Q2 2011
May 05, 2011: Synta Pharmaceuticals Reports Net Loss Of $11.4m For Q1 2011
Apr 04, 2011: Synta Announces Ganetespib Results At AACR
Mar 11, 2011: Synta Reports Net Loss Of $8.8m For Q4 2010
Mar 10, 2011: Insmed Reports Net Loss Of $5.8m For Q4 2010
Dec 01, 2010: Synta Pharmaceuticals Announces Senior Managemen Changes
Nov 04, 2010: Synta Pharmaceuticals Reports Net Loss Of $10.2 Million For Q3 2010
Sep 30, 2010: Synta Pharmaceuticals Appoints Donald Kufe To Board
Aug 09, 2010: Synta Reports Net Loss Of $9.1 Million For Q2 2010
May 24, 2010: Synta Announces Clinical Data Presentations At ASCO
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Synta Pharmaceuticals Corp., Key Facts
Synta Pharmaceuticals Corp., Key Employees
Synta Pharmaceuticals Corp., Key Employee Biographies
Synta Pharmaceuticals Corp., Major Products and Services
Synta Pharmaceuticals Corp., Number of Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Number of Pipeline Products by Development Stage
Synta Pharmaceuticals Corp., Pipeline Products By Therapy Area and Development Phase
Synta Pharmaceuticals Corp., History
Synta Pharmaceuticals Corp., Key Competitors
Synta Pharmaceuticals Corp., Ratios based on current share price
Synta Pharmaceuticals Corp., Annual Ratios
Synta Pharmaceuticals Corp., Interim Ratios
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Synta Pharmaceuticals Corp., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Pipeline Products by Development Phase
Synta Pharmaceuticals Corp., Performance Chart (2006 - 2010)
Synta Pharmaceuticals Corp., Ratio Charts
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

Infinity Pharmaceuticals, Inc.
Abbott Laboratories
Pfizer Inc.
Amgen Inc.
Johnson & Johnson
Onyx Pharmaceuticals, Inc.
Advanced Life Sciences holdings, Inc.

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile